Loading quotes...
Forecast
| Buy |
1 |
| Hold |
1 |
| Sell |
0 |
News Go to news feed
Scilex Holding grants Vivasor revolving credit facility of $20 million
Scilex Holding has agreed a revolving credit facility of up to $20 million to Vivasor, which Vivasor can draw in tranches for up to 120 months after the facility becomes effective. Disbursements are at Scilex’s sole discretion and may be funded in cash, tradable Scilex securities or Datavault shares; the interest rate is 5% p.a. The SEC filing also states that Dr. Henry Ji is CEO of both companies and that Scilex simultaneously signed a term sheet for a planned $100 million investment with iHolding, while the company has high indebtedness and a low liquidity ratio. » More on de.investing.com
Scilex signs term sheet for $100 million investment from iHolding of Kazakhstan
Scilex has signed a binding term sheet with iHolding Group LLP for a proposed $100 million capital increase. iHolding is to acquire newly issued shares at $15.00 per share, representing a 92% premium to the current price and would almost double the market capitalization. The proceeds are intended for expansion in healthcare and medtech, product development, acquisitions, working capital and IP expansion. The transaction remains subject to conditions such as due diligence, contractual closings, board approvals, shareholder consent and regulatory approvals. » More on de.investing.com
Datavault AI receives $120 million financing from Scilex to expand edge network
Datavault AI has signed a binding term sheet for $120 million in capital from Scilex. In return, Scilex receives revenue participation rights (30% of gross revenues up to $250 million, then 15% up to $1.2 billion, and thereafter 5%). The funds are intended to build a quantum-capable edge network infrastructure in about 100 U.S. cities; Datavault has secured Nvidia GPUs with a market value of $1.2 billion and is using Available Infrastructure’s micro-edge data centers with zero-trust and quantum-resistant encryption. Initial deployments in New York and Philadelphia are planned for Q2 2026, with expansion envisaged to 25 sites within 12 months and 100 within 36 months after closing; the deal is to be completed in tranches through the end of 2026. » More on de.investing.com
Financials
| (EUR) | June 2026 | YoY |
|---|---|---|
| Revenue | 6.7m | 20.25% |
| Gross profit | 986.61k | 82.44% |
| Net profit | -99.45m | 36.20% |
| EBITDA | -23.29m | 31.94% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €14.77m |
Number of shares | 7.03m |
52-week high/low | €24.13 - €2.03 |
| Dividends | No |
Beta | 1.79 |
P/E ratio | -0.04 |
PEG ratio | 0.00 |
P/B ratio | -0.05 |
P/S ratio | 0.52 |
Company profile
Scilex Holding Company, a biopharmaceutical company, focuses on developing and commercializing non-opioid management products for the treatment of acute and chronic pain. Its commercial product is ZTlido 1.8%, a prescription lidocaine topical product for the relief of neuropathic pain related with post-herpetic neuralgia, which is a form of post-shingles nerve pain. It also offers SP-102, a viscous gel formulation of corticosteroid for epidural injections that is in a Phase III clinical trial to treat lumbosacral radicular pain; SP-103, which is in Phase II clinical trail for the treatment of low back pain; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation that has completed Phase I clinical trial for the treatment of fibromyalgia. The company is headquartered in Palo Alto, California. Scilex Holding Company is a subsidiary of Sorrento Therapeutics, Inc.
| Name | Scilex Holding |
| CEO | Henry H. Ji |
| Headquarters | Palo Alto,
ca USA |
| Website | |
| Sector | Health Care |
| Industry | Biotechnology |
| IPO | 05/03/2021 |
| Employees | 34 |